Effective smoking cessation interventions for COPD patients: a review of the evidence
- PMID: 22046497
- PMCID: PMC3205559
- DOI: 10.1258/shorts.2011.011089
Effective smoking cessation interventions for COPD patients: a review of the evidence
Abstract
Objectives: To review the effectiveness of smoking cessation interventions offered to chronic obstructive pulmonary disease (COPD) patients, and identify barriers to quitting experienced by them, so that a more effective service can be developed for this group.
Design: A rapid systematic literature review comprising computerized searches of electronic databases, hand searches and snowballing were used to identify both published and grey literature.
Setting: A review of studies undertaken in north-western Europe (defined as: United Kingdom, Ireland, France, Germany, Benelux and Nordic countries).
Participants: COPD patients participating in studies looking at the effectiveness of smoking cessation interventions in this patient group, or exploring the barriers to quitting experienced by these patients.
Method: Quantitative and qualitative papers were selected according to pre-specified inclusion and exclusion criteria, critically appraised, and quantitative papers scored against the NICE Levels of Evidence standardized hierarchy.
Main outcome measure: Percentages of successful quitters and length of quit, assessed by self-report or biochemical analysis. Among qualitative studies, identified barriers to smoking cessation had to be explored.
Results: Three qualitative and 13 quantitative papers were finally selected. Effective interventions and barriers to smoking cessation were identified. Pharmacological support with Buproprion combined with counselling was significantly more efficacious in achieving prolonged abstinence than a placebo by 18.9% (95% CI 3.6-26.4%). Annual spirometry with a brief smoking cessation intervention, followed by a personal letter from a doctor, had a significantly higher ≥1 year abstinence rate at three years among COPD patient smokers, compared to smokers with normal lung function (P < 0.001; z = 3.93). Identified barriers to cessation included: patient misinformation, levels of motivation, health beliefs, and poor communication with health professionals.
Conclusion: Despite the public health significance of COPD, there is a lack of high-quality evidence showing which smoking cessation support methods work for these patients. This review describes three effective interventions, as well as predictors of quitting success that service providers could use to improve quit rates in this group. Areas that would benefit from urgent further research are also identified.
Figures
References
-
- Halbert RJ, Isonaka S, George D, Iqbal A Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003;123:1684–92 - PubMed
-
- World Health Organization Top Ten Causes of Death. Fact sheet No. 310. Geneva: WHO, 2008. See http://www.who.int/mediacentre/factsheets/fs310/en/index.html (last checked 18 August 2010)
-
- Caverley P COPD. : British Lung Foundation Lung Report III – Casting a shadow over the nation's health. London: British Lung Foundation, 2003:13–15
-
- European Respiratory Society Part 2: Major Respiratory Diseases. In: European Lung White Book. Sheffield: European Respiratory Society, 2003:34–43
-
- Wouters EF Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003;97 (Suppl. C):3–14 - PubMed
LinkOut - more resources
Full Text Sources